Timothy J.r. Harris

Biography

He is a molecular biologist and biochemist, and is currently a Venture Partner with SV Life Sciences and acting EVP R&D at Bioverativ. He was until March 2016, the SVP for Precision Medicine at Biogen. He was before that SVP of Translational Medicine at Biogen Idec.  Until 2011, he was the Chief Technology Officer (CTO) and Director of the Advanced Technology Program (ATP) at SAIC-Frederick, Inc. in Maryland which operates the National Cancer Institute’s leading center for cancer and AIDS research (now Frederick National Laboratory operated by Leidos Inc.,).  He has served as President and Chief Executive Officer (CEO) of Novasite Pharmaceuticals, and he founded SGX Pharmaceuticals in 1999 (formerly Structural Genomix), where he built the company to more than 130 employees, raised $85M in capital, and generated more than $20M in revenue during six years as CEO before it was sold to Eli Lilly.  Before founding SGX, Dr. Harris was Senior Vice President, Research and Development at Sequana/Axys.  He began his scientific career working on animal viruses such as foot & mouth disease and was one of the first molecular biologists (1981) at Celltech (now UCB Pharma) in the United Kingdom. He subsequently spent five years at Glaxo Group Research as Director of Biotechnology from 1989 to 1993. He is currently on the Board of Directors of Opgen (Nasdaq: OPGN) and is a visiting Professor at Columbia University, New York.  

Research Interest

 Molecular Biology,Biochemistry